Search results
-
J&J tries to outdo Tecvayli
… or AL amyloidosis Monotx (uncontrolled) Data at ASCO 2025: 100% ORR with RP2D in BCMA/GPRC5D-naive pts …
- 12/04/2025 - 11:28 -
Caribou finds a match
… up 25%, but later on Monday it was trading flat. Since ASCO 2025, where the Antler update had been expected before …
- 11/05/2025 - 12:59 -
Bispecific cytokine delivers for Innovent at last
… “We are marginally more positive on IBI363 after ASCO 2025, but note [that] IL-2 is not high on the …
- 10/23/2025 - 16:19 -
Few pancreatic Gleams of hope for Vyloy
… Solid tumours Monotx Gastric cancer data at ASCO 2025 Source: OncologyPipeline. …
- 10/16/2025 - 12:32 -
Takeda’s cancer prospects dim further
… mimetic Polycythemia vera Ph3 Verify presented at ASCO 2025, filing due in H2 2025 Licensed from …
- 10/03/2025 - 10:43 -
ESMO 2025 preview – Enhertu's early breast hat-trick
… vs chemo + Herceptin + Perjeta Data presented at ASCO 2025; PDUFA date 23 Jan 2026 LBA18 …
- 09/30/2025 - 14:20 -
Zelgen’s DLL3 trispecific goes pivotal
… Suzhou Zelgen China ph2 data in 3rd-line SCLC at ASCO 2025: ORR 63% & 58% with 10mg & 30mg respectively; ph3 …
- 10/02/2025 - 14:19 -
Joyo starts its first pivotal trial
… x CD8 fusion protein, in relapsed cervical cancer. At ASCO 2025 the company reported two partial responses in this …
- 09/25/2025 - 12:14 -
J&J goes straight into phase 3 in prostate
… T-cell engager, possibly because phase 1 data presented at ASCO 2025 suggested that pasritamig could offer a safer … or chemo Pasritamig, uncontrolled Data presented at ASCO 2025 Source: OncologyPipeline & …
- 09/16/2025 - 14:56 -
World Lung 2025 – Ideaya challenges Zai Lab
… ph1 Presentation venue World Lung 2025 ASCO 2025 ORR* 72% (52/72)** 51% (38/74)^ …
- 09/09/2025 - 10:02
